Semaglutide Investigated for Weight, Glucose Control, and Insulin Reduction in Type 1 Diabetes
Semaglutide Treatment in Type 1 Diabetes
Background
Type 1 Diabetes (T1D) management primarily relies on exogenous insulin, which can lead to weight gain and increased risk of hypoglycemia and diabetic ketoacidosis. Despite advances, achieving optimal glycemic control without these adverse effects remains challenging. GLP-1 receptor agonists like semaglutide have shown benefits in Type 2 Diabetes, including weight loss and improved glucose regulation, suggesting potential as an adjunct therapy in selected T1D individuals to address these unmet needs.